News
INO
1.925
-0.79%
-0.015
Here are the major earnings after the close today
Seeking Alpha · 8h ago
Options Volatility and Implied Earnings Moves This Week, May 12 – May 15, 2025
TipRanks · 1d ago
Weekly Report: what happened at INO last week (0505-0509)?
Weekly Report · 1d ago
Earnings week ahead: PLUG, CSCO, WMT, BABA, AMT, JD, TCEHY, and more
Seeking Alpha · 2d ago
Inovio Pharmaceuticals Inc. Stock Slips 8.1%, Underperforms Competitors
Dow Jones · 05/06 20:33
Inovio Pharmaceuticals Inc. Stock Slips 3.1%, Underperforms Competitors
Dow Jones · 05/05 20:35
Weekly Report: what happened at INO last week (0428-0502)?
Weekly Report · 05/05 09:26
Weekly Report: what happened at INO last week (0421-0425)?
Weekly Report · 04/28 09:28
Bet on These 5 Top-Ranked Stocks With Rising P/E
NASDAQ · 04/21 11:40
Weekly Report: what happened at INO last week (0414-0418)?
Weekly Report · 04/21 09:29
Inovio Pharmaceuticals Inc. Stock Advances 9.9%, Outperforms Competitors
Dow Jones · 04/14 20:33
Weekly Report: what happened at INO last week (0407-0411)?
Weekly Report · 04/14 09:26
Inovio (INO) Upgraded to Buy: Here's What You Should Know
NASDAQ · 04/09 16:00
INOVIO PHARMACEUTICALS, INC. FORM 10-K
Press release · 04/07 11:13
Weekly Report: what happened at INO last week (0331-0404)?
Weekly Report · 04/07 09:26
Inovio Pharmaceuticals Inc. Stock Rallies 10.7%, Outperforms Competitors
Dow Jones · 04/02 20:32
Inovio Pharmaceuticals Inc. Stock Slips 5.8%, Underperforms Competitors
Dow Jones · 03/31 20:33
Weekly Report: what happened at INO last week (0324-0328)?
Weekly Report · 03/31 09:29
Inovio Pharmaceuticals Inc. Stock Sheds 3.7%, Underperforms Competitors
Dow Jones · 03/25 20:34
Weekly Report: what happened at INO last week (0317-0321)?
Weekly Report · 03/24 09:26
More
Webull provides a variety of real-time INO stock news. You can receive the latest news about Inovio Pharmaceu through multiple platforms. This information may help you make smarter investment decisions.
About INO
More
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
Recently
Symbol
Price
%Change